PRODUCTS & INNOVATION
By connecting FreeStyle Libre system with Novo Nordisk insulin pens, we’re improving diabetes management.
Feb 20 2019
For people living with diabetes and using an insulin pen, questions abound throughout the day:
What is my glucose level?
When was my last dose of insulin?
Should I take another now?
But the question that stands above all: Why can’t there be a better way?
Abbott and Novo Nordisk have an answer: There can be.
And soon, there will be.
By combining the technology behind our FreeStyle Libre system — which is the fastest growing continuous glucose monitoring system (CGM) on the market with more than 1.3 million users1 — with Novo Nordisk’s connected insulin pens, managing your diabetes is going to get a whole lot easier.
"Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors," said Anders Dyhr Toft, corporate vice president, Commercial Innovation, Novo Nordisk. "With partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient's individual diabetes management and can help people with diabetes feel more confident in their treatment."
This is what the next frontier in diabetes management looks like:
FreeStyle Libre system has been described as our ultimate wearable. It's a CGM that comes calibrated and doesn't require fingersticks2. With the FreeStyle LibreLink app, you can capture real-time glucose levels, eight-hour history and see how your glucose levels are changing throughout the day.
Combine that with Novo Nordisk's latest connected pens that give users accurate dosages and an injection history that includes size and time of your last dose, keeping your last 800 doses.
Given the large and growing base of FreeStyle Libre users, this partnership between Abbott and Novo Nordisk has the potential to significantly improve diabetes management, giving users the ability to be better informed and personalize their care with technology at their fingertips.
"It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "Diabetes is a time intensive condition to manage. People with diabetes must make a variety of decisions every single day about their glucose monitoring, nutrition, insulin and medication intake.
"By enabling insulin dosing data from Novo Nordisk's connected pens to be shared with our digital health tools, we’ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life."
How soon will our devices work together to better help you manage your diabetes? We're working as quickly as possible. It's an exciting development and we wanted to share with you what's on the horizon with our smart technology.
For important safety information about the FreeStyle Libre system in the US, please click here.
For more about Novo Nordisk, please visit novonordisk.com.
1. Data on file, Abbott Diabetes Care.
2. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose.
Study: HbA1c Drops With Use of FreeStlye Libre
Android™ App Joins FreeStyle Libre Family
Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.